Back

PCSK9 inhibitors: the story continues.

27 August 2017 (18:30 - 18:40)
Organised by:
Congress Presentation Part of: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention Endothelial function Open Access ESC Congress 2017

About the speaker

Photo
Professor John Chapman

Pitie Salpetriere APHP University Hospital, Paris (France)

2 More presentations in this session

Presentation thumbnail
Challenging the data.
Professor J. Chapman (Paris, FR) Professor P. Sever (London, GB)
Presentation thumbnail
PCSK9 inhibitors: more volumes to come?
Professor J. Chapman (Paris, FR)

Access the full session

Session thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention

The Event

Event poster

ESC Congress 2017

27 August 2017 18:30 CET
You may be interested in
thumbnail
Congress Presentation
PCSK9 inhibition: new insights
1 September 2024
thumbnail
Congress Presentation
PCSK9 inhibitors and incidence of arrhythmias in clinical practice: a phase IV multicentric study
18 April 2023
thumbnail
Webinar
LDL-C reduction postACS: strike early and strike strong
15 November 2021
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources